Compare MXC & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MXC | INTS |
|---|---|---|
| Founded | 1972 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.8M | 24.0M |
| IPO Year | N/A | 2023 |
| Metric | MXC | INTS |
|---|---|---|
| Price | $10.80 | $0.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.33 |
| AVG Volume (30 Days) | 3.6K | ★ 2.0M |
| Earning Date | 02-06-2026 | 11-06-2025 |
| Dividend Yield | ★ 0.90% | N/A |
| EPS Growth | ★ 39.24 | N/A |
| EPS | ★ 0.79 | N/A |
| Revenue | ★ $7,429,923.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.99 | ★ N/A |
| Revenue Growth | ★ 7.26 | N/A |
| 52 Week Low | $5.89 | $0.19 |
| 52 Week High | $16.00 | $3.17 |
| Indicator | MXC | INTS |
|---|---|---|
| Relative Strength Index (RSI) | 64.00 | 51.40 |
| Support Level | $9.61 | $0.39 |
| Resistance Level | $10.80 | $0.41 |
| Average True Range (ATR) | 0.63 | 0.03 |
| MACD | 0.08 | -0.00 |
| Stochastic Oscillator | 59.90 | 94.49 |
Mexco Energy Corporation is an independent oil and gas company. It is engaged in the acquisition, exploration, development, and production of natural gas and crude oil properties located in the United States. The company carried out its operation in the Permian Basin of West Texas. It is focusing on two primary areas, the Delaware Basin located in the Western portion of the Permian Basin including Lea and Eddy Counties, New Mexico and Loving County, Texas, and the Midland Basin located in the Eastern portion of the Permian Basin including Reagan, Upton, Midland, Martin, Howard, and Glasscock Counties, Texas. The company generates revenue from Oil sales, Natural gas sales, oil and gas royalty interests.
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.